Principal investigator of Aladote® study James Dear presents calmangafodipir as a potential new treatment for late stage liver toxicity after acetaminophen overdose at liver disease conference
October 4, 2017
PledPharma AB Company Announcement Principal investigator of Aladote® study James Dear presents calmangafodipir as a potential new treatment for late stage liver toxicity after acetaminophen overdose at liver disease conference Stockholm, 2017-10-04 09:05 CEST (GLOBE NEWSWIRE) -- PledPharma announces that an abstract presenting preclinical data for calmangafodipir has been accepted for presentation at a major international liver meeting in Washington DC during October 20-24, 2017. The work was a collaboration between Dr. James Dear and his group at the University of Edinburgh and PledPharma. The abstract, “Calmangafodipir is a new treatment for late stage liver toxicity after acetaminophen overdose”, has received acceptance for presentation of results from the preclinical study and the design of the ongoing clinical study at the 68th Annual Meeting of AASLD*, October 20-24, 2017 in Washington, DC, USA. The presentation will cover preclinical data indicating that calmangafodipir could be used as an effective treatment for acetaminophen poisoning in patients who present late to hospital when standard of care antidote (acetylcysteine, NAC) has lost efficacy. Based on the preclinical data, a proof of principle study with the focus on safety and tolerability in patients attending hospital following an acetaminophen overdose has started at the Edinburgh Royal Infirmary and the first patient was included in June. “The fact that the Abstract has been selected for presentation at the liver meeting underlines the importance of the interesting pre-clinical data for calmangafodipir as a potential new treatment modality for acetaminophen (paracetamol) overdose patients and illustrates the growing interest in treating this patient group.” says Nicklas Westerholm, CEO PledPharma AASLD information: Session ID: Parallel Session 1 Session Title: Drug and Herbal Induced Liver Injury Session Date and Time: Oct 22, 2017 8:00 AM - 9:30 AM Abstract Number: 14 *AASLD stands for the American Association for the Study of Liver Diseases. AASLD is referred to “The Liver Meeting”. For more information, please contact: Nicklas Westerholm, CEO, phone: +46 73 354 20 62 Nicklas.westerholm@pledpharma.se Michaela Gertz, CFO, phone: +46 709 26 17 75 Michaela.gertz@pledpharma.se About PledPharma PledPharma develops new drugs that protect the body against oxidative stress – a potentially debilitating and sometimes life-threatening condition that can be caused by chemotherapy treatment and following acetaminophen (paracetamol) overdose. The company's most advanced project PledOx® is being developed to reduce nerve damage associated with chemotherapy. A phase IIb study has been conducted and will serve as the basis for the continued development. The drug candidate Aladote® is being developed to reduce the risk of acute liver failure associated with acetaminophen poisoning. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company’s Certified Adviser (tel +46 8 463 80 00). For more information, see www.pledpharma.se
